PMS2 and neoplasm: Furthermore, the combination of PRMT5i with CPT‐11 elicited a dMMR‐like state and activated cGAS‐STING signaling in a PMS2‐dependent manner, which subsequently enhanced CD8+ T cell‐mediated anti‐tumor immunity and increased sensitivity to αTIGIT treatment.